Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tom Feys"'
Autor:
Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille
Publikováno v:
Pharmaceutics, Vol 12, Iss 2, p 194 (2020)
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leuk
Externí odkaz:
https://doaj.org/article/86efcb9c5e2f4835884c8341b7c9f981
Autor:
Tom Feys
Publikováno v:
European Medical Journal. :33-36
Treatment decisions in chronic myeloid leukaemia (CML) are complex and require the evaluation of many factors at each stage of therapy. Many patients will become resistant or intolerant to the first and subsequent lines of tyrosine kinase inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9493aa6f38a6040ad71b46d2adb956d5
https://doi.org/10.33590/emj/10310682
https://doi.org/10.33590/emj/10310682
Autor:
Yves Beguin, X Poire, Gils Roex, Tessa Kerre, Tom Feys, Philippe Lewalle, Dominique Bron, Peter Vandenberghe, Sébastien Anguille
Publikováno v:
Pharmaceutics
Pharmaceutics, 12 (2
Pharmaceutics, Vol 12, Iss 2, p 194 (2020)
PHARMACEUTICS
Pharmaceutics, 12 (2
Pharmaceutics, Vol 12, Iss 2, p 194 (2020)
PHARMACEUTICS
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5007e41d3dd935c7a64fee1a7facb3
https://hdl.handle.net/10067/1661960151162165141
https://hdl.handle.net/10067/1661960151162165141
Autor:
Tom Feys, Bruce Poppe, Katleen De Preter, Nadine Van Roy, Bruno Verhasselt, Pascale De Paepe, Anne De Paepe, Frank Speleman
Publikováno v:
Haematologica, Vol 92, Iss 7 (2007)
Background and Objectives Classical Hodgkin’s lymphoma (cHL) is a common malignant lymphoma characterized by the presence of large, usually multinucleated malignant Hodgkin and Reed Sternberg (HRS) cells which are thought to be derived from germina
Externí odkaz:
https://doaj.org/article/cdbb7bc05f884e2497eb2a9d20779186
Autor:
Bruce Poppe, Pascale De Paepe, Anne De Paepe, Tom Feys, Franki Speleman, Bruno Verhasselt, Katleen De Preter, Nadine Van Roy
Publikováno v:
HAEMATOLOGICA
Background and Objectives Classical Hodgkin's lymphoma (cHL) is a common malignant lymphoma characterized by the presence of large, usually multinucleated malignant Hodgkin and Reed Sternberg (HRS) cells which are thought to be derived from germinal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cedafd4ea856305ca74b3def46646244
https://doi.org/10.3324/haematol.11073
https://doi.org/10.3324/haematol.11073
Publikováno v:
Euroclear Holding SA/NV MarketLine Company Profile. 9/25/2024, p1-16. 16p.
Autor:
Caifu Chen, Jo Vandesompele, Nathalie Bernard, Pieter Mestdagh, Simone Guenther, Franki Speleman, Tom Feys
Publikováno v:
Nucleic Acids Research
MicroRNAs (miRNAs) are an emerging class of small non-coding RNAs implicated in a wide variety of cellular processes. Research in this field is accelerating, and the growing number of miRNAs emphasizes the need for high-throughput and sensitive detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d2e791985ce6bb78953ab047f3d348
http://europepmc.org/articles/PMC2588502
http://europepmc.org/articles/PMC2588502
Publikováno v:
Euroclear Holding SA/NV MarketLine Company Profile. 9/2/2023, p1-15. 15p.
Autor:
RUST, SUSANNA
Publikováno v:
Investment & Pensions Europe - IPE. Sep2021, Special Section p20-21. 2p.
Autor:
Roex, Gils1 (AUTHOR) gils.roex@uantwerpen.be, Feys, Tom2 (AUTHOR) t.feys@ariez.com, Beguin, Yves3 (AUTHOR) yves.beguin@chu.ulg.ac.be, Kerre, Tessa4 (AUTHOR) tessa.kerre@ugent.be, Poiré, Xavier5 (AUTHOR) xavier.poire@uclouvain.be, Lewalle, Philippe6 (AUTHOR) philippe.lewalle@bordet.be, Vandenberghe, Peter7 (AUTHOR) peter.vandenberghe@uzleuven.be, Bron, Dominique6 (AUTHOR) dominique.bron@bordet.be, Anguille, Sébastien1,8 (AUTHOR) sebastien.anguille@uza.be
Publikováno v:
Pharmaceutics. Feb2020, Vol. 12 Issue 2, p194. 1p.